Press Releases

Jan 6, 2017 • 7:35 AM EST Matinas BioPharma to Present at Biotech Showcase™ 2017

Dec 8, 2016 • 7:05 AM EST Matinas BioPharma Receives Contract Award from Cystic Fibrosis Foundation Therapeutics to Study MAT2501 for the Treatment of NTM-Infection in Pre-Clinical Models of CF

Dec 5, 2016 • 7:05 AM EST Matinas BioPharma Commences Dosing in Phase 1 Study of Orally Administered Aminoglycoside Antibiotic MAT2501

Nov 21, 2016 • 7:05 AM EST Matinas BioPharma Initiates Enrollment and Commences Patient Dosing in Phase 2 Study of MAT2203 for the Treatment of Vulvovaginal Candidiasis

Nov 15, 2016 • 7:05 AM EST Matinas BioPharma Reports 2016 Third Quarter Financial Results and Provides Corporate Update

Nov 3, 2016 • 7:35 AM EDT Matinas BioPharma Researchers Among Rutgers University Recipients of 2016 Edison Patent Awards

Oct 26, 2016 • 7:35 AM EDT Matinas BioPharma Presents Preclinical Data of Orally Administered Encochleated Influenza Vaccine in Murine Model at IDWeek 2016

Oct 24, 2016 • 7:05 AM EDT Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology

Oct 13, 2016 • 7:05 AM EDT Matinas BioPharma to Present at the 2nd Annual Dawson James Securities Growth Stock Conference

Sep 28, 2016 • 7:00 AM EDT Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203